Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Bahamas STEM News.
Press releases published on November 4, 2025
Datavault AI, Music Dash 및 NFHITS, 특허받은 Inaudible Tones®, AI 및 블록체인 기술을 통해 음악 데이터 추적·표시·수익화 혁신 추진
필라델피아, Nov. 05, 2025 (GLOBE NEWSWIRE) -- via IBN – 인공지능(AI) 기반 데이터 시각화, 가치평가, 수익화 분야를 선도하는 Datavault AI Inc.(나스닥: DVLT)가 NFHITS와 협력해 독자적인 웹 3.0(Web 3.0) 기반 음악 및 콘텐츠 유통 네트워크를 개발하기 시작했다고 오늘 발표했다. 이 네트워크는 민팅(minting)과 블록체인 기술을 핵심으로 구축된다. NFHITS는 수익화 파트너인 뮤직 …
Datavault AI, Music Dash dan NFHITS Bekerjasama untuk Mengubah Paparan Penjejakan Data Muzik dan Pengewangan melalui Inaudible Tones® yang Dipatenkan, AI dan Teknologi Blockchain
PHILADELPHIA, Nov. 05, 2025 (GLOBE NEWSWIRE) -- melalui IBN – Datavault AI Inc. (Nasdaq: DVLT), peneraju dalam visualisasi data, penilaian dan pengewangan yang dipacu oleh AI, hari ini mengumumkan bahawa ia telah memulakan kerjasama dengan NFHITS untuk …
Datavault AI, Music Dash และ NFHITS จับมือกันปฏิวัติการติดตาม แสดงผล และสร้างรายได้จากข้อมูลเพลง ผ่านเทคโนโลยี Inaudible Tones® ปัญญาประดิษฐ์ (AI) และเทคโนโลยีบล็อกเชนที่ได้รับการจดสิทธิบัต…
ฟิลาเดลเฟีย, Nov. 05, 2025 (GLOBE NEWSWIRE) -- ผ่านทาง IBN – Datavault AI Inc. (Nasdaq: DVLT) ผู้นำด้านการแสดงผล การประเมินมูลค่า และการสร้างรายได้จากข้อมูลที่ขับเคลื่อนด้วย AI ประกาศในวันนี้ว่า บริษัทได้เริ่มความร่วมมือกับ NFHITS …
Datavault AI 与 Music Dash 及 NFHITS 达成合作，通过专利产品 Inaudible Tones®、AI 与区块链技术变革音乐数据追踪、展示与变现模式
费城, Nov. 05, 2025 (GLOBE NEWSWIRE) -- 通过IBN发布 -- AI 驱动型数据可视化、价值评估与变现领域的领军企业 Datavault AI Inc.（Nasdaq：DVLT）今日宣布，其已开始与 NFHITS 展开合作，共同开创基于 Web 3.0、链上铸造及区块链的音乐与内容分发网络。 NFHITS 及其变现合作伙伴 Music Dash 的使命是引领音乐与电影产业迈入一个创意、技术与机遇深度融合的新时代。 …
Datavault AI、Music Dash 與 NFHITS 合作利用專利 Inaudible Tones®、人工智能及區塊鏈技術，革新音樂數據追蹤展示及盈利化模式
費城, Nov. 05, 2025 (GLOBE NEWSWIRE) -- 透過 IBN 發佈 -- 在人工智能 (AI) 驅動數據可視化、估值及盈利化領域引領在前的 Datavault AI Inc. (Nasdaq: DVLT) 今天宣佈，已開始與 NFHITS 展開合作，聯手開創專有的 Web 3.0 鑄造及區塊鏈音樂與內容分發網絡。 NFHITS 與其盈利化合作夥伴 Music Dash 密切合作，致力引領音樂與電影產業邁向新世代，實現創意、科技與機遇的相匯共融。 …
Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results
Durable symptom and tissue responses observed out to 52 weeks following a single treatment with EP-104GI Enrollment continues in Phase 2b portion of the RESOLVE Trial, with topline data expected by Q3 2026 Completed $80.5 million public offering supported …
Mawson Infrastructure Group Inc. Announces Written Court Order of Dismissal of Involuntary Chapter 11 Petition
MIDLAND, Pa., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Mawson Infrastructure Group Inc. (NASDAQ: MIGI) (“Mawson” or the “Company”), a U.S.-based technology company that designs, builds, and operates next-generation digital infrastructure platforms providing …
Acceleware Announces Participation in the MICA Conference & Innovation Showcase 2025: Mining's New Frontiers
CALGARY, Alberta, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Acceleware Ltd. (“Acceleware” or “Company”) (TSX-V: AXE) announced today that Mike Tourigny, Chief Operations Officer, will present at the 4th Annual Mining Innovation Commercialization Accelerator (MICA) …
DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Châtillon, France, November 4, 2025 DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage …
DBV Technologies participera à la 2e conférence annuelle Guggenheim Healthcare Innovation
Châtillon, France, le 4 novembre (22 :30 CET) 2025 DBV Technologies participera à la 2e conférence annuelle Guggenheim Healthcare Innovation DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market : DBVT— CUSIP : 23306J309), une …
iRhythm Technologies to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that its management team is …
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced …
Orezone Provides Notice of Third Quarter 2025 Results
VANCOUVER, British Columbia, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Orezone Gold Corporation (TSX: ORE | ASX: ORE | OTCQX: ORZCF) will announce its third quarter 2025 results on Wednesday, November 12, 2025, after TSX market close. The Company will host a …
3D Systems Reports Third Quarter 2025 Financial Results
ROCK HILL, S.C., Nov. 04, 2025 (GLOBE NEWSWIRE) -- 3D Systems Corporation (NYSE:DDD) announced today its financial results for the third quarter ended September 30, 2025. Revenue of $91.2 million driven by sequential growth in hardware printer sales and …
HP Inc. to Announce Fourth Quarter Fiscal 2025 Earnings on Nov 25, 2025
PALO ALTO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- HP Inc. (NYSE: HPQ) will present a live audio webcast of a conference call to review financial results for the fourth fiscal quarter and fiscal year ended October 31, 2025 on Tuesday, Nov 25, 2025 at 5: …
Anaptys Announces Participation in November Investor Conferences
SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of …
Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update
Announced intent to separate biopharma operations from substantial royalty assets by YE 2026 Phase 2 top-line data through Week 12 for rosnilimab, a pathogenic T cell depleter, in ulcerative colitis on track for Nov./Dec. 2025 Phase 2b data for rosnilimab …
Synchronoss Technologies Reports Third Quarter 2025 Results
Net Income of $5.8 Million and Diluted EPS of $0.51 Per Share Revenue of $42.0 Million, Including 93.8% Recurring Revenue Company Reiterates Expectation of Adding a New Customer in 2025 Additional Tier 1 Customer Signing Expected in First Half of 2026 …
Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Reported positive interim Phase 1 results for SPY003, a next-generation anti-IL-23 antibody, demonstrating the molecule was well-tolerated and exhibited an ~85-day half-life supporting quarterly or twice annual maintenance dosing Initiated Phase 2 SKYWAY …
Sana Biotechnology to Present at the TD Cowen Immunology & Inflammation Summit
SEATTLE, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the TD Cowen Immunology …